Investment Rating - The industry rating is "Outperform the Market" (maintained rating) [5] Core Viewpoints - Infrastructure investment continues to show high growth, with significant increases in water, electricity, fuel, and thermal investments, as well as water conservancy investments, which have seen year-on-year growth rates of +25.5% and +30.7% respectively in the first four months of 2025 [1][2] - The issuance of special bonds has accelerated, with a cumulative increase of 1,190.4 billion yuan in special bonds in the first four months of 2025, an increase of 467.9 billion yuan year-on-year, leading to optimism about the conversion of physical workload in infrastructure [1] - The report emphasizes the cyclical investment opportunities in coal chemical industries and suggests paying attention to the transformation opportunities of certain small and medium-sized construction companies [1] Summary by Sections Real Estate and Construction Data - From January to April 2025, real estate sales area decreased by 2.8% year-on-year, with new construction area down by 23.8% and construction area down by 9.7% [2] - In the same period, the completion area saw a year-on-year decline of 16.9% [2] Cement Industry - Cement production in the first four months of 2025 was 495 million tons, a decrease of 2.8% year-on-year, with April's production down by 5.3% [3] - The average cement shipment rate was 36%, remaining stable year-on-year, but the price pressure continues due to weak market demand [3] Glass Industry - Flat glass production from January to April 2025 was 31.86 million weight boxes, down 4.8% year-on-year, with April's production also declining [4] - The market demand for float glass was weak, leading to increased inventory levels among producers [4]

Group 1 - The core viewpoint of the news is the performance and structure of the China Europe CSI All-Share Healthcare Equipment and Services Index Fund A, which has experienced a slight decline recently [1] - As of May 19, the fund's latest net value is 1.05 yuan, marking a continuous drop for four trading days with a cumulative decline of 1.26% [1] - The fund was established in August 2024 with a total size of 0.13 billion yuan and has achieved a cumulative return of 4.82% since inception [1] Group 2 - The fund's holder structure shows that institutional investors hold 0.10 billion shares, accounting for 91.94% of the total shares, while individual investors hold 0.01 billion shares, making up 8.06% [1] - As of March 31, 2025, the top ten holdings of the fund account for a total of 41.48%, with major investments in companies such as Mindray Medical (9.10%), Aier Eye Hospital (7.77%), and United Imaging Healthcare (6.36%) [3]

证券代码：600529 证券简称：山东药玻 编号：2025-031 山东省药用玻璃股份有限公司 关于职工代表监事换届选举的公告 山东省药用玻璃股份有限公司监事会 2025年5月17日 本公司监事会及全体监事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 山东省药用玻璃股份有限公司（以下简称"公司"）于2025年5 月15日上午在公司研发大楼六楼会议室，以现场结合通讯表决方式召 开公司2025年第一次职工代表团长会议，会议通知于2025年5月6日以 通讯方式向全体职工代表团长发出，会议应到代表团长10名，现场实 到代表团长8名，2名代表团长以通讯方式进行了表决。经会议投票民 主选举，选举陈茂斌先生为公司第十一届监事会职工代表监事，与公 司2024年年度股东大会选举产生的监事共同组成公司第十一届监事 会，任期同股东大会选举产生的监事一致。 备案文件：公司2025年第一次职工代表团长会议决议。 特此公告。 ...

北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话：010-88004488/66090088 传真：010-66090016 邮编：100005 北京国枫律师事务所 关于山东省药用玻璃股份有限公司 2024 年年度股东大会的 法律意见书 1 国枫律股字[2025]A0201 号 致：山东省药用玻璃股份有限公司（贵公司） 北京国枫律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出席并见 证贵公司 2024 年年度股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东大会规则》（以下简 称"《股东大会规则》"）、《律师事务所从事证券法律业务管理办法》（以下简称"《证 券法律业务管理办法》"）、《律师事务所证券法律业务执业规则（试行）》（以下简 称"《证券法律业务执业规则》"）等相关法律、行政法规、规章、规范性文件及《山 东省药用玻璃股份有限公司章程》（以下简称"《公司章程》"）的规定，就本次会议 的召集与召开程序、召集人资格、出席会议人员资格、会议表决程序及表决结果等事宜， 出 ...

证券代码：600529 证券简称：山东药玻 公告编号：2025-032 山东省药用玻璃股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 5 月 16 日 (二)股东大会召开的地点：山东省淄博市沂源县城药玻路 1 号山东药玻公司研 发大楼辅楼会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： 审议结果：通过 | 表决情况： | | --- | | 股东类型 | 同意 | | 反对 | | 弃权 | | | --- | --- | --- | --- | --- | --- | --- | | | 票数 | 比例（%） | 票数 | 比例 | 票数 | 比例 | | | | | | （%） | | （%） | | A 股 | 163,275,444 | 98.2474 | 2,432,800 | 1.4638 | 479,700 | 0.2888 | 2 ...

证券代码：600529 证券简称：山东药玻 编号：2025-034 第二部分、监事会会议审议情况 本次会议以记名投票方式审议通过了《关于选举公司第十一届监 事会主席的议案》，经全体监事推选，选举陈茂斌先生为公司第十一 届监事会主席, 任期三年，自本次监事会审议通过之日起，至公司第 十一届监事会任期届满日止。 表决结果：同意3票，反对0票，弃权0票。 第三部分、备查文件 1、山东省药用玻璃股份有限公司第十一届监事会第一次会议决 议。 山东省药用玻璃股份有限公司 第十一届监事会第一次会议决议公告 本公司监事会及全体监事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 第一部分、监事会会议召开情况 山东省药用玻璃股份有限公司（以下简称"公司"）第十一届监 事会第一次会议于2025年5月16日下午在公司研发大楼六楼会议室以 现场结合通讯方式召开，全体监事一致同意豁免本次会议通知时限， 会议应到监事3名，现场实到监事2名,1名监事通讯表决。本次会议经 参会监事推举，由监事陈茂斌先生主持，董事会秘书列席会议，会议 程序符合《公司法》和《公司章程》的有关规定。 ...

证券代码：600529 证券简称：山东药玻 编号：2025-033 山东省药用玻璃股份有限公司 第十一届董事会第一次会议决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 山东省药用玻璃股份有限公司第十一届董事会第一次会议通知， 经全体董事一致同意，豁免本次会议通知时限。会议于2025年5月16 日下午在公司研发大楼六楼会议室以现场结合通讯方式召开，会议应 到董事9名，现场实到董事7名,2名董事通讯表决。本次会议经全体董 事推选由扈永刚先生主持，会议程序符合《公司法》和《公司章程》 的有关规定。 二、董事会会议审议情况 经全体董事审议和表决，一致形成如下决议： 1、选举扈永刚先生为公司第十一届董事会董事长，任期三年， 自本次董事会审议通过之日起，至公司第十一届董事会任期届满日 止。 表决结果：9票同意、0票弃权、0票反对。 | 专业委员会 | 主任委员（召集人） | 委员 | | --- | --- | --- | | 审计委员会 | 孙宗彬 | 冯加友、陈茂鑫 | | 薪酬与考核委员会 | ...

Investment Rating - The report maintains a "Positive" outlook for the building materials industry [2] Core Insights - The building materials sector continues to experience historical lows in 2024 and 2025, but signs of improvement are emerging [4][12] - Revenue for the building materials sector in 2024 is projected at CNY 682.93 billion, a year-on-year decline of 12.41%, ranking second to last among 31 industries [4][16] - In Q1 2025, the sector's revenue decline narrowed to 1.60%, with a revenue of CNY 129.83 billion, improving its ranking to 18th among industries [5][40] - The net profit margin and return on equity (ROE) are at historical lows, with the sector's net profit margin dropping to 2.61% in 2024 [25][28] Summary by Sections 1. Industry Performance Overview - The building materials sector's revenue and net profit continue to decline in 2024, remaining at the bottom of industry rankings [4][16] - Q1 2025 shows a narrowing revenue decline and improvements in net profit and cash flow, with a net profit of -CNY 243 million, a 74.02% year-on-year increase [5][44] 2. Segment Performance - In Q1 2025, segments like cement and glass fiber show positive revenue growth, with cement revenue up 0.11% and glass fiber up 25.24% [6][55] - Most segments, except for pipes, show improvements in net profit year-on-year, with cement, glass fiber, refractory materials, and coatings ending their respective revenue declines [6][58] 3. Investment Strategy - The report suggests that leading companies in the sector can achieve better growth in a challenging environment through internal and external development strategies [8][81] - The anticipated recovery of the real estate sector is expected to stabilize demand for building materials, leading to valuation recovery in the industry [8][84] - Recommended companies include Beixin Building Materials, Weixing New Materials, Shandong Pharmaceutical Glass, and others [8][84]

Core Insights - The pharmaceutical packaging industry in China is experiencing steady growth, with the market size projected to reach 143.96 billion yuan in 2024, driven by the expansion of the domestic pharmaceutical market and the rapid development of the pharmaceutical industry [2] - Long-term growth prospects for the pharmaceutical packaging market are supported by factors such as an aging population, increased health awareness, and improvements in the healthcare system, leading to a rising demand for pharmaceuticals and consequently for packaging [2] Industry Definition and Classification - Pharmaceutical packaging refers to a range of materials and containers used to protect drugs, facilitate storage and transportation, promote sales, provide drug information, and ensure medication safety [2] - It conveys important information regarding the quality, safety, and efficacy of the drugs through its design, materials, and structure [2] Industry Chain Analysis - The pharmaceutical packaging industry chain includes multiple sectors: raw material supply, packaging material manufacturing, drug packaging and application, and auxiliary processes [4] - The upstream sector involves the supply of raw materials such as plastics, glass, metals, and paper, which are crucial for the stability and quality of packaging materials [4] - The midstream sector processes these raw materials into various packaging forms, ensuring properties like sealing and moisture resistance [4] - The downstream sector includes pharmaceutical manufacturers and distributors who utilize these packaging materials for drug sales [4] - The industry is evolving towards environmentally friendly, intelligent, and personalized packaging solutions due to rising environmental awareness and technological advancements [4] Development History - The development of the pharmaceutical packaging industry in China has gone through three stages: initial development, rapid expansion, and transformation and innovation [6] - The initial stage was characterized by reliance on imports and limited technology, while the rapid expansion phase saw increased competition and the introduction of advanced management practices [6] - Currently, the industry is focused on transformation, with increased R&D investment and a shift towards eco-friendly and smart packaging solutions, marking a transition from technology catch-up to innovation leadership [6] Related Reports - The report by Zhiyan Consulting analyzes the competitive landscape and investment potential of the pharmaceutical packaging industry, aiming to identify future market trends and development potential [8] - It provides a comprehensive analysis of the industry’s operational status, import and export dynamics, and competitive structure, projecting trends for 2025 [10]

证券代码：600529 证券简称：山东药玻 公告编号：2025-030 山东省药用玻璃股份有限公司 关于部分闲置募集资金购买理财产品到期赎回的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 公司于 2024 年 4 月 20 日召开了第十届董事会第十二次会议和第 十届监事会第十次会议，并于 2024 年 5 月 16 日召开了 2023 年年度 股东大会，审议通过了《关于使用闲置募集资金购买理财产品的议案》， 同意公司使用总额度不超过人民币 10 亿元的暂时闲置募集资金进行 购买安全性高、流动性好、期限不超过 12 个月（含）的保本型理财 产品（包括但不限于协定性存款、结构性存款、定期存款、通知存款、 大额存单等），并在上述额度内滚动使用，募集资金理财使用额度及 授权的有效期为自议案经公司 2023 年年度股东大会审议通过之日起 12 个 月 内 有 效 。 具 体 内 容 详 见 公 司 在 上 海 证 券 交 易 所 网 站 （www.sse.com.cn）披露的《山东省药用玻璃股份有限公司关于使用 闲置募集资金 ...